The liver's capacity to silently accumulate dangerous fat deposits has emerged as one of the most underrecognized health crises facing modern adults, with implications extending far beyond liver function to cardiovascular disease and cancer risk. This comprehensive medical review reveals how a condition most people have never heard of may be quietly undermining the health of nearly half the adult population.
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum from simple fat accumulation to inflammatory liver damage called MASH. The condition affects 30-40% of all adults globally, with dramatically higher rates among those with metabolic disorders: 60-70% of people with type 2 diabetes and 70-80% of those with obesity carry this liver burden. Diagnosis relies on ultrasound detection of hepatic fat combined with at least one metabolic syndrome feature, provided alcohol consumption remains below 2-3 drinks daily for women and men respectively.
This prevalence data suggests MASLD has become the default state for metabolically compromised adults rather than an exceptional condition. The review positions this as the world's most common chronic liver disease, representing a fundamental shift in how liver pathology intersects with modern lifestyle patterns. Unlike traditional liver diseases with clear external causes, MASLD emerges from the internal metabolic chaos of insulin resistance, dyslipidemia, and central obesity. The condition's stealth progression—often remaining asymptomatic until advanced stages—makes it particularly insidious, as millions unknowingly harbor progressive liver damage that compounds their cardiovascular and cancer risks through complex inflammatory pathways.